We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

UNI:MILUNIPOL ASSICURAZIONI SPA Analysis

Data as of 2026-06-25 - not real-time

€24.32

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Unipol Assicurazioni is trading at €24.32, just below its 30‑day resistance of €24.85 and comfortably above the 20‑day SMA of €22.99, indicating a bullish price trend reinforced by a bullish MACD crossover (0.75 vs 0.65) and a solid RSI of 64.9. Valuation metrics show a forward PE of ~11.0 versus an industry average of 16.9, suggesting the stock is undervalued relative to peers, while the dividend yield of 4.66% and a payout ratio under 42% point to a sustainable income stream. Risk indicators reveal a low beta of 0.57, but a 30‑day volatility of 32% and decreasing volume hint at short‑term price fragility.
On the fundamentals side, the company benefits from an A‑Excellent rating by AM Best and a strategic acquisition of Banca Monte dei Paschi branches, which could broaden its bancassurance footprint. Strong operating margins (12.7%) and a profit margin of 13.8% support earnings stability, while the debt‑to‑equity ratio of 46.7% remains manageable given €1.8 bn of cash. Together, these factors justify a strong‑buy consensus from analysts and a target mean price of €25.22, indicating upside potential despite current proximity to recent highs.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near resistance with decreasing volume
  • Bullish technicals but elevated short‑term volatility
  • Sustained dividend yield

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Undervalued valuation relative to industry peers
  • Strategic acquisition expanding bancassurance channels
  • Strong credit rating (A‑Excellent) supporting financial stability

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Consistent dividend policy with healthy payout ratio
  • Blend of value and growth attributes from acquisitions and margin strength
  • Low beta indicating limited market‑wide risk over extended horizon

Key Metrics & Analysis

Financial Health

Revenue Growth-2.10%
Profit Margin13.84%
P/E Ratio12.0
Debt/Equity46.74
P/B Ratio1.7
Industry P/E16.9

Technical Analysis

TrendBullish
RSI64.9
Support€20.35
Resistance€24.85
MA 20€23.00
MA 50€22.40
MA 200€20.15
MACDBullish
VolumeDecreasing
Fear & Greed Index89.16

Valuation

Target Price€25.22
Upside/Downside3.69%
GradeUndervalued
TypeBlend
Dividend Yield4.66%

Risk Assessment

Beta0.57
Volatility32.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.